Tuhura Biosciences, Inc. annual report, FY2019

Filing identity and reporting period

The supplied metadata identifies Tuhura Biosciences, Inc. and “2018 Q4,” but the filing text is DelMar Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended June 30, 2019. This summary reflects the filing, not the metadata. The company was a clinical-stage biotechnology business developing VAL-083; it reported no product revenue.

Financial results and liquidity

Margins are not meaningful because the company had no revenue. The balance sheet showed current liabilities of $2.07 million, consisting mainly of accounts payable, accrued liabilities and related-party payables; no material interest-bearing debt balance is identified in the supplied text. The company reported an accumulated deficit of $60.58 million.

Changes versus prior year and financing

Net loss narrowed by about $3.09 million. R&D expense fell 49%, primarily because the company discontinued its STAR-3 Phase 3 study and had lower clinical, personnel, preclinical, intellectual-property and travel costs. G&A expense rose 17%, including $555,664 of professional fees for a rights offering that was later terminated, as well as higher personnel and other costs. Operating cash use declined, but year-end cash and working capital also decreased.

In June 2019, the company raised approximately $3.2 million net from a registered direct offering and received about $0.7 million net from warrant exercises. After year-end, an August 2019 public offering generated approximately $6.7 million net; the company said this was expected to fund operations into the fourth quarter of calendar 2020 and full enrollment in its ongoing Phase 2 studies by that quarter. The filing states that substantial doubt about continuing as a going concern, which existed at June 30, was alleviated by the subsequent offering, while also noting that additional funding would be required.

Business, outlook and material developments

• VAL-083 was the company’s principal development candidate, being studied in MGMT-unmethylated glioblastoma (GBM), a group with limited effective treatment options. Two open-label Phase 2 programs covered newly diagnosed patients receiving radiation, adjuvant treatment, and recurrent disease. These were early, non-controlled studies; reported observations do not establish efficacy.
• In the China first-line Phase 2 study, the company reported that, among 17 of the first 20 enrolled patients with an assessment as of August 1, 2019, nine had an investigator-assessed complete response, seven stable disease and one progression. Sixteen of 20 were alive at the data cutoff. These preliminary results require confirmation and comparison with appropriate clinical endpoints and follow-up.
• In the recurrent MD Anderson study, enrollment was 56 of up to 83 patients as of July 24, 2019. The starting dose was reduced from 40 to 30 mg/m² to improve tolerability and potentially permit more treatment cycles. The adjuvant arm had begun enrollment. Management anticipated presenting study data in late 2019 and the first half of 2020.
• The company discontinued its STAR-3 Phase 3 study, citing enrollment, patient-selection and probability-of-success concerns, and redirected resources toward biomarker-driven Phase 2 studies.
• The ovarian-cancer program was under reassessment despite an FDA-allowed IND; the company was evaluating strategic options, including combinations with PARP inhibitors. NSCLC and other indications remained potential future opportunities.
• VAL-083 had FDA Fast Track designation for recurrent GBM and orphan-drug designations for glioma, medulloblastoma and ovarian cancer. These designations are not marketing approvals. China commercial rights were held through a collaboration, but the Chinese manufacturing partner had not met the company’s stated U.S. manufacturing-quality standards; the company reported obtaining drug supply made under cGMP conditions from third-party manufacturers.
• After Nasdaq notified the company of an equity deficiency in May 2019, the company reported that the Nasdaq Hearings Panel confirmed compliance on September 6, 2019 following financing. The company also completed a 1-for-10 reverse split and increased authorized common shares from 7 million to 95 million during the fiscal year.

Risks, contingencies and governance matters

• The company remained pre-revenue and dependent on external capital; further financing could dilute shareholders, impose restrictive terms or prove unavailable.
• Development depended heavily on one candidate, and clinical results, enrollment, regulatory acceptance, manufacturing and commercialization remained uncertain. Myelosuppression, especially thrombocytopenia and neutropenia, was the principal reported toxicity.
• The filing identifies a material weakness in internal control over financial reporting, related to insufficient segregation of duties. Management said it was using an external consulting firm and continued remediation, but controls were still considered ineffective at June 30, 2019.
• Manufacturing relied on a limited number of third parties, with no established backup manufacturer. Other risks included competition, intellectual-property challenges, reimbursement uncertainty, foreign-exchange exposure and potential Nasdaq listing compliance issues.
• The company reported no legal proceedings and no off-balance-sheet arrangements. It reported $659,343 in clinical-development commitments and month-to-month office rent.

Investor verification checklist

• Confirm that this DelMar Pharmaceuticals filing is the intended filing; it does not match the Tuhura Biosciences metadata or the stated 2018 Q4 period.
• Review audited financial statements and subsequent-event disclosures to verify the August financing proceeds, warrant and share issuances, and the reported operating runway.
• Track patient enrollment, follow-up, safety, endpoint definitions and controlled or historical comparisons for each Phase 2 study; treat interim response figures as preliminary.
• Check progress in remediating the material weakness and whether subsequent filings report effective controls.
• Assess future cash requirements, dilution from outstanding securities, study commitments and the status of Nasdaq listing compliance.